news

  • 25 September 2019
    Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update

    Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period ending 30 June 2019, prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union, and an outlook for the remainder of the year.

    Download the full press release


Back to our news

Related

Sequana

Sequana Medical announces first patient enrolled in North American alfapump® pivotal study (POSEIDON)

Sequana Medical appoints leading experts as Heart Failure Scientific Advisors

Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

Sequana Medical to host webcast on 27 May 2019

Sequana Medical announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis

Sequana Medical announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress

Sequana Medical announces 2018 Full Year Results and 2019 Outlook

Sequana Medical raises €27.5 million in successful Initial Public Offering

Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM and existing shareholders

Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society

Sequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites.

Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study

Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD

Sequana Medical Announces Publication of Results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T)

Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study for the alfapump® vs. Large Volume Paracentesis for Refractory Ascites in Journal of Hepatology

Sequana Medical Announces Sudden Passing of Founder, President & CEO

Ian Crosbie Joins Sequana Medical as Chief Financial Officer

Former Bayer and Pharmacia Senior Executive Rolf A. Classon Joins the Sequana Medical AG Board as Chairman

Sequana Medical AG Raises CHF 9 million (USD 9.3M) in a Series C Extension - Transaction Includes New Investors Salus Partners and Quest for Growth

Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump® system.

Sequana Medical’s new alfapump technology improves the care of patients with challenging refractory ascites

Sequana Medical AG raises CHF 23 million in a Series C financing led by LSP, and adds an Independent Board Chairman and Vice President of Sales and Marketing.

Sequana Medical appoints Vingmed/ViCare Medical as distributor of the alfapump® system in Scandinavia

University of Modena and Reggio Emilia implant Italy’s first patients with Sequana Medical’s alfapump® system

Sequana Medical receives CE-mark approval for the use of its alfapump® system in cancer patients with malignant ascites

University Hospital Zurich and University Inselspital Berne implant their first patients with Sequana Medical’s ALFApump® System

Sequana Medical’s ALFApump® System proves to be a safe and efficacious breakthrough technology in ascites management

Sequana Medical’s ALFApump® System receives reimbursement in Germany for breakthrough technology in ascites management

Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards

NHS National Innovation Centre estimates Sequana Medical’s ALFApump® System could save the NHS £50 million in ascites care annually

The Medical University of Vienna and Vienna General Hospital perform the first two commercial implants worldwide of Sequana Medical’s ALFApump® System

Sequana Medical receives CE Mark Approval for the ALFApumpTM System and adds key executive to team

NovaShunt announces the launch of its new corporate identity: Sequana Medical